Biotech | May 16, 2022
Antengene announces commercial availability of Xpovio in China
The drug will be available in 600 hospitals and 105 DTPs
The drug will be available in 600 hospitals and 105 DTPs
The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
Revolutionary ovarian cancer rapid test available Q4 2022
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
Saumen is a postgraduate in management from IIM, Ahmedabad and an executive fellow in management from ISB, Hyderabad
Subscribe To Our Newsletter & Stay Updated
